UK biotech firm Kymab Group Limited, a monoclonal antibody biopharmaceutical group, has secured a $100 million (£81 million) Series C financing from China’s ORI Healthcare Fund L.P. (ORI Fund), a Chinese sector-focused fund that was launched by former investment banker at Goldman Sachs.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
